$SUPN

Supernus Pharmaceuticals and Indivior Pharmaceuticals agreed to a tax-free, all-stock merger of equals creating a CNS-focused company. Pro forma annual revenue is about $2.2B, adjusted EBITDA $888M, with $125M annual cost synergies. Supernus Inc. will trade on Nasdaq as SUPN, with closure expected Q4 2026. Indivior shareholders receive a $1B special cash dividend funded via a $650M Citibank term loan.

Stocks settled sharply higher as Middle East tensions eased. The article cites a 66% chance of a +25 bp FOMC hike (Sept 15-16) and an 88% chance of an ECB +25 bp hike (Sept 10). WTI fell over 5%, lifting 10-year Treasuries and lowering yields. It also lists major movers including META (+6%), ORCL (+9%), and ATKR (+28%) after a $3.8B deal.

Markets were mixed as investors priced a 63% chance of a 25 bp FOMC hike on Sept. 15-16. U.S. 10-year yields fell to 4.688% and German bunds and UK gilts moved lower. Airline and cruise stocks rose as WTI dropped over 6%. Software gained, while semiconductors and energy fell. Notable movers included ATKR (+28%) on a $3.8B Prysmian deal and CNH (+16%) raising EPS guidance.

Markets rose as investors priced in easing geopolitical risks and US economic strength. The article cites a 63% chance of a +25 bp FOMC hike and notes US 10-year yields fell to 4.682%. It highlights stock moves including Meta (+5%), Amazon (+4%), and ATKR surging after Prysmian agreed to buy for $3.8B.

Supernus Pharmaceuticals and Indivior agreed to merge in a deal valued at about $1.8 billion. Indivior shareholders will receive 0.2683 Supernus shares each, a stated ~58% premium. Supernus shareholders will own ~58% and Indivior ~42%. Closing is expected in H2 2026, pending approvals, with ~$125 million annual cost synergies by end-2027.

Indivior (INDV) agreed to a tax-free, all-stock merger with Supernus (SUPN). Indivior shareholders will own about 56.5% and Supernus 43.5%. The combined CNS-focused company is expected to close in Q4 2026 and trade on Nasdaq under SUPN. Pro forma: ~$2.2B revenue, $888M adjusted EBITDA, $125M synergies. Indivior Q2 2026: adj. EPS $1.15, revenue $343M.

Supernus Pharmaceuticals and Indivior are planning an all-stock merger to form a CNS-focused biopharma. The deal is expected to produce pro forma net revenue of $2.2bn and about $125m in annual cost synergies. Supernus brings Qelbree and Gocovri; Indivior brings Sublocade, Suboxone and Opvee. If completed in Q4 2026, the combined firm will trade as SUPN on Nasdaq.

Supernus Pharmaceuticals (NASDAQ:SUPN) is set to report earnings Tuesday after market close. The prior quarter saw revenue of $207.7M, up 38.6% YoY, but EPS missed expectations. For the upcoming quarter, analysts expect revenue growth of 24.3% YoY. The article cites an average analyst price target of $63.50 versus a $45.01 share price.

Indivior and Supernus outlined a proposed tax-free all-stock “merger of equals” between the two companies. Indivior plans to file an SEC Form S-4 with a joint proxy statement/prospectus, and both firms will submit additional SEC documents. Shareholders will receive the definitive joint proxy statement/prospectus when available.

Supernus Pharmaceuticals (SUPN) rose 3% after announcing a definitive, tax-free all-stock merger with Indivior Pharmaceuticals (INDV), expected to close in Q4 and subject to approvals. The combined portfolio would include 11 FDA-approved drugs. Supernus reported Q2 revenue up 32% to just over $219M, but a net loss of over $58M and a miss versus EPS profit estimates.